Is MRD Negativity the New Benchmark in ALL Treatment Strategies?

Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL. 

Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation.